Ticker

Bamco Inc. NY increased its position in shares of Veradermics, Incorporated (NYSE: MANE) by 284.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 229,581 shares of the company's stock after acquiring an additional 169,913 shares during the period. Bamco Inc. NY owned

Veradermics, Incorporated (NYSE: MANE - Get Free Report) Director John Childs sold 100,000 shares of Veradermics stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $107.12, for a total transaction of $10,712,000.00. Following the sale, the director directly owned 194,117 shares in the company, valued at $20,793,813.04. This

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and clinical progress. “In the second quarter of 2026, we made significant advancements in the…

MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for hair loss. However, VDPHL01 still needs pivotal data to make it ready for a potential FDA submission. If approved, VDPHL01 would compete as a cash-pay prescription treatment for pattern hair loss, which would let MANE tap into a sizeable TAM.